1-SA | Systematic Literature Review of the Humanistic Burden of Hemophilia A and B | Caitlyn Matuska | Received |
1-RWD | A Global Data and Secured Data Environment Technology Framework to Support Healthcare Decision-Making with Real-World Data | Bettina Taxell | Received |
1-OP | Electroencephalogram (EEG) Cup Electrode Application: A Multicenter Prospective Study | David Hoffman | Received |
2-MT | Real-World Evidence (RWE) in Action: A Review of Australias Health Technology Assessment (HTA) of Non-Drug Health Technologies | Jasmine Watson | Received |
2-HTA | Developing a System-Centric Framework for Health Technology Value Creation | Caitlin Main | Received |
3-OP | Development of a Taxonomy Tool for Standardising HTA Terminology within SUSTAIN-HTA | Saif Elayan | Received |
3-HSD | Real-World Treatment Patterns in Sickle Cell Disease (SCD) in Europe, Africa, Eastern Mediterranean Region (EMR), and India: A Systematic Literature Review (SLR) | sarah ronnebaum | Received |
3-PCR | The Psychosocial Burden of Severe Hypoglycemic Events and Impaired Awareness of Hypoglycemia in Adult Continuous Glucose Monitor Users: Results From a Cross-Sectional Survey Study | Zara Petzoldt | Received |
3-CO | Minimal Residual Disease in Untreated, Physically Fit Chronic Lymphocytic Leukemia (CLL) Patients (Fit Subpopulation): Results of a Systematic Review With Bayesian Network Meta-Analysis | Anita Stozek-Tutro | Received |
4-MT | Improving Patient Access to Care: Single-Use Rhinolarygnoscopes Implemented in SLP Practice | Ian Haislip | Received |
4-CO | The True Value of Living Systematic Reviews (LSRs): A Case Report Within Systemic Lupus Erythematosus (SLE) | Colleen Dumont | Received |
5-HPR | Visualizing Reimbursement Criteria for Digital Health Tools in Belgium and France | Barbara Dhaene | Received |
5-PCR | Patient Perspective About Perceived Impact and Quality of Life in Chronic Kidney Disease | Ana Rita Pedro | Received |
5-RWD | Perspectives on Disease Burden Among Informal Care Partners of People With Mild Cognitive Impairment or Dementia Due to Alzheimers Disease: A Real-World Survey | Diego Novick | Received |
5-EPH | The Burden of Severe Symptomatic Aortic Stenosis in Spain: Can Capacity-Enhancing Innovations Play a Role in Addressing the Growing Demand for Treatment? | Archita Sarmah | Received |
6-MSR | Descriptives vs Statistics in Utility Analyses: A Simulation | Colleen Dumont | Received |
6-OP | Analysis of Pharmaceutical Company Actions in Asia-Pacific to Improve Patient Access | Jasmine Watson | Received |
7-RWD | Real-World Data Sources for Oncology in Five Major European Countries: A Targeted Literature Review | Eric Meadows | Received |
8-HPR | The Payment for Performance Environment for Drugs and Medical Devices in Romania | Ciprian Paul Radu | Received |
9-MSR | Meta-Analysis of Pre-Post Studies: Why Standardized Mean Difference Should be Avoided | Caitlyn Matuska | Received |
10-HSD | Reimbursement of Remote Health Services in Turkiye | hande can | Received |
10-HPR | Assessing the Pricing Trends of Repurposed Medicines in the United Kingdom | Cillian Copeland | Received |
10-PCR | Humanistic Burden of Radical Cystectomy (RC) Among Patients With Non-Muscle Invasive (NMIBC) or Non-Metastatic Muscle Invasive Bladder Cancer (MIBC): A Systematic Literature Review (SLR) | Colleen Dumont | Received |
10-HTA | HTA Considerations for Large Language Models in Healthcare | Caitlyn Matuska | Received |
10-CO | Characterizing the Burden and Unmet Need of Membranous Nephropathy | Jasmine Watson | Received |
10-MT | Coverage With Evidence Development as a Potential Solution for the Reimbursement of Digital Therapeutics (DTx)? A Systematic Review of Pathways to Inform Reimbursement Decisions in Major European Healthcare Systems | Roman Spelsberg | Received |
11-CO | Delayed Graft Function: More Than Just a Kidney Transplant Complication? | Jasmine Watson | Received |
11-HTA | Early Access Programs (EAPs) in France: Reasons for Refusal | Gavin Outteridge | Received |
11-PT | Authoring of Peer-Reviewed Articles on the Experiences of Patients With Rare Diseases by Patients and Their Caregivers: A Rapid Review | Kawthar Nakayima | Received |
11-SA | A Targeted Literature Review of the Clinical and Humanistic Burden of Polymyalgia Rheumatica and the Associated Unmet Medical Needs | Sarah Jane Mckenna | Received |
11-MT | The Impact of High-Plex Point-of-Care Diagnostic Testing for Acute Respiratory Tract Infections in German Emergency Departments: An Early Cost-Consequence Analysis | sophie vandepitte | Received |
12-MT | Developing and Applying Predictive Models to Identify Patients at Increased Risk of Falling in Domiciliary Care | Tomas Heger | Received |
12-CO | Predictors of Treatment and Recovery Among Obese Patients in the United States: A Retrospective Observational Study Using the PINC AI Healthcare Database (PHD) | Gui Lopes | Received |
12-EE | Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Protection of Infants in the United States (US) | Ahuva Averin | Received |
12-RWD | Next Generation RWE: What Factors Are Essential to Fully-Federated and AI-Enabled RWE and Outcomes Research? | Dustin O Dell | Received |
13-HSD | Patient Characteristic, Treatment Pattern, and Healthcare Resource Utilization of Obstructive Hypertrophic Cardiomyopathy (HCM) in China on a Cardiologist Survey | Joanne Wu | Received |
13-SA | A Non-Systematic Review of Equity in Oncology HTA Submissions to NICE | Kathleen Bowes | Received |
14-EPH | Gastrointestinal Endoscopy Volume, Efficiency, and Safety Issues: A Case Report | David Hoffman | Received |
14-MT | Reusable Flexible Bronchoscope Setup and Reprocessing: A Multicenter Prospective Study | David Hoffman | Received |
14-HSD | Understanding Physicians Decision Making Processes When Treating Mild -to-Moderate Chronic Kidney Disease: A Qualitative Study | Keila Meginnis | Received |
15-OP | Evaluating the Economic Impact of Real-World Costs in nAMD Treatment Using Neutral Theory: A UK Perspective | Ravi Jandhyala | Received |
15-HPR | Innovative Rebate Management in Oncology Drug Budgets: Streamlining Operations and Enhancing Financial Efficiency Through Technology in Newfoundland and Labradors Cancer Care Program | Ina Hasani | Received |
15-MT | Thought Viruses: A Mental Self-Help App | Eva González-Correa | Received |
15-PT | Utilization Trends and Access Disparities in CAR T-Cell Therapy: Real-World Insights From an All-Payer US Healthcare Database (2017-2024) | Gui Lopes | Received |
15-RWD | Densifying the Patient Journey by Integrating Data of Oncology Patients From Multiple Data Sources Through Confidential Computing | Holger Gothe | Received |
15-HTA | Oncology Patient and Caregivers Perspectives on Value Assessment Frameworks: A Qualitative Study | Colleen Cuthbert | Received |
15-PCR | Exploring the Development, Evaluation, and Impact of Researcher-Led Patient and Family Advisory Councils in Cancer Research | Christie Farrer Rogers | Received |
16-HPR | Performance Indicators for the Assessment of Ageing-in-Place Reform Policies: A Scoping Review and Evidence Map | Isabelle Vullings | Received |
16-PCR | Does Baseline Disease Severity Impact the Meaningful Score Difference of Clinical Outcome Assessments? Results From Studies in Two Itching-Related Skin Conditions | Carla Dias-Barbosa | Received |
16-SA | Automating Systematic Literature Review Abstract Screening Using Large Language AI Models: A Development and Validation Study | Maisie Borrows | Received |
16-MT | Contrasting Evidence Requirements for Early Access Schemes for Digital Health Technologies in the UK and Germany: A Challenge for Multi-Market Evidence Generation Planning | Jasmine Watson | Received |
17-EPH | Targeted Literature Review (TLR) on the Mortality in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) in the USA | Ali Siddiqui | Received |
17-MSR | Can Machine Learning Support Survival Model Selection to Inform Economic Evaluations? Exploring K-Fold Cross Validation Based Model Selection in Seven Datasets | Sabine Grimm | Received |
17-MT | Assessing the Value of Switching Dialysis Center to a Central Delivery System With 220L Drum: A Kingdom of Saudi Arabia (KSA) Case Study | Jovana Petrovic | Received |
18-MSR | Exploring the Sensitivity of Utility Scores Predicted by the EQ-5D, SF-6D, HUI3, 15D, AQoL4D and AQoL8D Multiattribute Utility Instruments to SF-36 Dimensions | Josephine Tetteh | Received |
18-EPH | Assessment of Cardiovascular Events in Patients With Severe COPD Exacerbations | Ali Siddiqui | Received |
18-SA | Determining If Delphi Panel Qualitative Insights Can Be Useful When Informing Drug Pricing Related Decisions in the Drug Development Stage | Jasmine Watson | Received |
19-OP | Assessing the Application of Artificial Intelligence Techniques for Systematic Reviews and Meta-Analyses | Xuan Wang | Received |
19-RWD | Assessing the Ability of Hospital Sites From a European Real-World Network to Support Oncology Evidence Generation | Adil Ajmal | Received |
19-PCR | Evaluating the Treatment Patterns Among Patients With Non-Valvular Atrial Fibrillation (NVAF) Prescribed Apixaban or Warfarin by Race/Ethnicity in Commercially Insured Patients Using Komodo Healthcare Map Data | Julie Wojciechowski | Received |
19-EPH | Ovarian Cancer Age-Adjusted Mortality Rates in Chile During 2002-2019 | Abbas Ali | Received |
19-MSR | Capturing Real-World Rare Disease Patient Journeys: Are Current Methodologies Sufficient for Informed Healthcare Decisions? | Kristen Cribbs | Received |
19-SA | Improving Real-World Evidence on Shared Decision Making Through Joint Clinician and Patient Reported Outcomes | Maureen Carlyle | Received |
20-HPR | Collaborative Demonstration Project in the Province of Québec for the Operationalization of Value-Based Agreement: Moving From a Vision to Implementation | Julie Frappier | Received |
20-RWD | The Use and Validation of Oncology Endpoint Proxies in Real-World Studies: Targeted Literature Review Mapping 64 Retrospective and Validation Real-World Studies | Eleanor Ralphs | Received |
20-HSD | Assessing the Impact of Staff Sentiment in Healthcare on Patient Safety Outcomes | Maisie Borrows | Received |
21-MSR | Comparing Methods for eGFR Slope Estimates Among Adult CKD Patients in a UK Electronic Health Record System: Challenges and Opportunities | Ling Zhang | Received |
21-EPH | Incidence of Lichen Sclerosus in Men: A Systematic Review | Immaculate Nevis | Received |
21-PCR | Clinical and Humanistic Burden of People With Severe Hemophilia A Treated With Prophylaxis in Europe: A Longitudinal Analysis From the Chess Studies | Charlotte Camp | Received |
22-SA | Mapping the Landscape of Distributional Cost-Effectiveness Analysis: A Systematic Review of Applications and Methodological Considerations | Maisie Borrows | Received |
23-PCR | Approaches to Participant Sampling in In-Trial Interviews | Brittany Klooster | Received |
23-HSD | Effectiveness of a Quality Improvement Collaboration With Community Nurses to Reduce Hospital Referrals Due to Tunnelled Haemodialysis Catheter Dysfunction | Yasmin Ng | Received |
23-RWD | Addition of Open Administrative Claims Significantly Improves Capture of Mortality in Electronic Health Record (EHR) Focused Real-World Data (RWD) | Yanina Natanzon | Received |
24-PCR | Vale Project Vascular Access Life Experience: Experience of Patients With Vascular Access for Hemodialysis | Geraldo Tadinho Monteverde Spencer | Received |
24-HPR | Use of Real-World Evidence to Support Regulatory Clearance of a Labeling Revision for Robotic-Assisted Radical Prostatectomy in the United States | Liza Gibbs | Received |
25-CO | PRO-WAVE1: Monitoring Patient Reported Outcomes (PROs) in Prostate Cancer Through Wave Health: A Novel ePRO Health Platform | Margaret Philen | Received |
25-EPH | US Benchmark Data on Healthcare System Encounter-Related Time Toxicity: Top Conditions at the Population Level | JoAnn Krenitsky | Received |
26-EE | Years of Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Algeria | Bernadette Pöllinger | Received |
26-CO | Encorafenib Plus Binimetinib Versus Dabrafenib Plus Trametinib in First-Line for Patients With Metastatic Non-Small Cell Lung Cancer Harboring BRAF V600E Mutation: Matching Adjusted Indirect Comparison of Pharos and BRF113928 | Meriem Boussahoua | Received |
27-EE | A Best Practice Guide to Cost-Effectiveness Modelling of CAR Ts in Large B-Cell Lymphoma | Brett Doble | Received |
27-SA | A Non-Systematic Review Evaluating Search Strategies Leveraged in HTA Submissions to NICE | Kathleen Bowes | Received |
27-PCR | Utility Estimates for Health-States Associated With Chronic Myeloid Leukemia: A Systematic Literature Review | Isabelle Lundqvist | Received |
28-PCR | Clinical and Humanistic Burden in Patients With Chronic Myeloid Leukemia in Early Lines of Treatment: A Literature Review | Isabelle Lundqvist | Received |
28-MT | Performance Metrics of a Novel Single-Use Therapeutic Gastroscope | David Hoffman | Received |
28-EPH | Revolutionizing Systematic Reviews: The Precision of LLMS in Screening Observational Studies | Cheryl Jones | Received |
28-HTA | Insights on Early Access Refusal in France | Jasmine Watson | Received |
29-PT | From European Union Joint Clinical Assessments to Local Health Technology Assessments: An Environmental Scan of Methodological Guidance Across Key European Markets | Colleen Dumont | Received |
29-SA | Pathways to Value and Impact for Child Health and Wellness | Deborah Marshall | Received |
29-EE | Efficiency of Secukinumab vs Adalimumab for Treating Hidroadenitis Suppurativa in Spain | Carles Blanch | Received |
29-MSR | Automated Data Extraction Using Artificial Intelligence to Accelerate Systematic Literature Reviews in Rheumatoid Arthritis | Mirko von Hein | Received |
30-PT | Navigating the New European Member State Coordination Group on Health Technology Assessment Quantitative Evidence Synthesis Guidelines | Victoria Paly | Received |
31-PCR | Is There Enough Focus on Capturing Data From Pediatric Patients and Their Caregivers in Non-Oncology Indications? | Jasmine Watson | Received |
31-MT | Comparison of Coverage With Evidence Development Approaches for Digital Health Technologies and Pharmaceuticals | Jasmine Watson | Received |
31-EE | A Systematic Literature Review of Economic Burden and Medication Adherence With Subcutaneous Versus Intravenous Oncology Therapies | Phillip Sarocco | Received |
32-MSR | Harnessing the Value of External Control Arms Beyond the Oncology and Rare Disease Settings | Colleen Dumont | Received |
32-CO | Linguists Perceptions of Human- and Machine-Translated Clinical Outcome Assessment (COA) Wording: A Mixed Methods Study | Tim Poepsel | Received |
32-MT | A Comparative Effectiveness Study of Two Narrow Profile Staplers Used in Video-Assisted Thoracoscopic Surgery Lobectomy | I-Wen Pan | Received |
33-EPH | Risk Factors for Psoriasis: An Umbrella Review of 12 Published Metanalyses | Stacey Chang-Douglass | Received |
33-RWD | Physician Perception of Patient Unmet Needs and Optimism Towards Gene Therapy: Results From a Multinational Real-World Survey | Sheena Thakkar | Received |
34-PCR | The Impact of Parastomal Hernia on Quality of Life Using Data From the Cipher Prospective Cohort Study | Joel Glynn | Received |
36-MSR | Data Visualization of Completion Rate for PRO Objectives in Oncology Clinical Trials Supporting PRO Estimands | Christopher Beard | Received |
37-EPH | Adult Vaccinations in Europe: Unfulfilled Potential | Karolina Skora | Received |
38-HSD | Continuity of Medication Care for Cancer Patients Through Outpatient Service Provision in Specialist Practices in Germany | Holger Gothe | Received |
39-EE | Cost-Consequence Model Comparing the Originator r-hFSH-alfa and Its Biosimilar for =4 Complete Ovarian Stimulation Cycles During Assisted Reproductive Technology Treatment in Spain, France, and Germany | Nany Gulati | Received |
40-CO | Efficacy and Safety of Difelikefalin in Patients Receiving Concomitant Opioid Medication | Thilo Schaufler | Received |
40-SA | European Multi-Country Real-World Effectiveness in Oncology Using Physician and Patient Survey Data: What Did We Learn? | Marion BONNET | Received |
41-MT | The Diagnostic Accuracy of Ultrasound and Genetic Tests for the Diagnosis of Autosomal Dominant Polycystic Kidney Disease: A Systematic Mapping Review | James Fotheringham | Received |
41-PT | Benefits of Inhaled Corticosteroids (ICS) in COPD Maintenance Combinations: Real-World Evidence Using Longitudinal Targeted Maximum Likelihood Estimation | Tara Cowling | Received |
41-HTA | The Use of the SF-36v2 Health Survey (SF-36), SF-12v2, and SF-6D in Health Technology Assessments | Lauren Crowder | Received |
42-CO | Comparison of Survival Outcomes for 177LuLu-PSMA-617 vs Other Systemic Treatments in Post-Taxane Metastatic Castration-Resistant Prostate Cancer Setting: A Bayesian Network Meta-Analysis | Valéry Risson | Received |
42-PCR | Multi-Disciplinary Approach to Develop an Ultra-Rare Disease Decision Aid | Jasmine Watson | Received |
42-RWD | Understanding the Treatment Landscape in Mild Cognitive Impairment/Alzheimers Disease Dementia and Physicians Opinions on Future Developments in Disease-Modifying Therapies: A Real-World Survey | Diego Novick | Received |
43-MT | HTA Requirements for Medical Technologies in Spain | Caitlyn Matuska | Received |
44-EE | The Economic and Environmental Burden of Hydrophilic and Hydrophobic IOLs in the UK | Derek OBoyle | Received |
45-MSR | Uptake of Artificial Intelligence in Health Economics and Outcomes Research | Zlatko Boni | Received |
45-RWD | Researcher Difficulties Using Secondary Data Sources to Generate Real-World Evidence: Results From an Online Survey | David Thompson | Received |
45-HTA | Defining Value in the Mental Illness Space: Is Caregiver Burden Considered in Health Technology Assessments of Treatments for Depression and Schizophrenia? | Jasmine Watson | Received |
46-PT | Development of Economic Evaluation Studies (EEs) in Saudi Arabia | Yazeed Alkhnizan | Received |
46-EPH | Urate Lowering Therapy in Patients With Subcutaneous Tophi | Robert Morlock | Received |
47-HPR | Does Orphan Drug Designation Lead to Reimbursement in EU5? | Sofia Huertas | Received |
47-MT | The Evaluation of Surgical Stapling in Robotic Thoracic Procedures: Clinical Outcomes and Resource Utilization | I-Wen Pan | Received |
47-SA | Clinical, Economic, and Humanistic Burden of SIDS/SUID in the USA and Europe | Stacey Chang-Douglass | Received |
48-CO | Population Impact of Performing HRR Testing for Metastatic Castration-Resistant Prostate Cancer Treatment in the US | Neo Su | Received |
49-CO | Evaluating Efficacy and Safety of RNA Therapies Lumasiran and Nedosiran in Patients With Primary Hyperoxaluria Type 1: A Systematic Literature Review | Ankit Gupta | Received |
50-RWD | Treatment Patterns and Outcomes of RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Selpercatinib in Europe: Interim Results From the SPRINT-RET Study | Grace Segall | Received |
50-MSR | Use of a Fine-Tuned, Clinical, Bidirectional Transformer (BERT) Large Language Model (LLM) to Classify the Patient and Caregiver Voice Through Their Social Media Health Posts: An Example in Non-Small Cell Lung Cancer (NSCLC) | Ashwin Rai | Received |
50-EE | NICE Cancer Drug Fund Exits: Insights Into the Outcomes of Cancer Drug Fund Reappraisals and the Use of Decision Modifiers | Elizabeth Thurgar | Received |
51-EPH | Evaluation of US/European Deprivation Indices Applications in Oncological, Health Economics, and Outcomes Research (HEOR) Studies | Jasmine Watson | Received |
52-HSD | Reducing Complications in Patients Living With Type 2 Diabetes by an Optimized Management of Weight and Glycemia and Their Associated Savings | Virginia Pascual | Received |
53-EPH | The Indirect Costs Related to HPV-Attributable Cancer Mortality in European Countries; Years of Life Lost, and Productivity Costs | Ugne Sabale | Received |
53-HTA | Trends Underlying Positive and Negative Decision-Making for New Oncology Treatments Appraised by the National Institute for Health and Care Excellence (NICE) in 2023 | Michael Tang | Received |
54-HSD | Epidemiology, Healthcare Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Claims Data Analysis in Germany From 2016 to 2021 | Carolina Schwedhelm | Received |
54-MT | Sleep Quality in Peritoneal Dialysis (PD) Patients and Its Associated Economic Burden for Society | Sophie Boeger | Received |
54-PCR | Psychometric Validation and Meaningful Within-Patient Change (MWPC) Thresholds for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Using Data from the EVOKE-01 Study | Shanen Stempel | Received |
55-MSR | Is Artificial Intelligence Ready to Tackle Language Barriers for HEOR Research? | Danny Yeh | Received |
55-PCR | The Burden of Long COVID on Quality of Life and Daily Functioning | Naomi Stapleton | Received |
55-HTA | A Targeted Review of the Challenges and Strategies for Submitting Patient-Generated Evidence to Health Technology Assessment (HTA) Agencies | Dorte Katrin Hering | Received |
56-MT | Economic Implications of Response and Non-Response to Cardiac Resynchronization Therapy With Dynamic Atrioventricular Optimization Algorithm Use | Zenichi Ihara | Received |
57-MSR | Leveraging Artificial Intelligence for the Generation of Computable Operational Definitions: Facilitating Real-World Evidence Research | Evelyn Rizzo | Received |
59-MT | Meek Micrografting in the German Hospital Setting: An Assessment of Recent Developments in Wound Management | David Stather | Received |
59-HSD | Addressing Postnatal Depression: Disparities in Treatment Availability | Jasmine Watson | Received |
60-MT | Artificial Intelligence-Based Tools Designed to Predict Future Mechanical Ventilation and/or Mortality in Hospitalised COVID-19 Patients: A Systematic Literature Review | Harriet Dickinson | Received |
61-SA | Inequalities by Gender and Overall Index of Multiple Deprivation (IMD) in Accessing Aortic Valve Replacement Remain Remarkable in England | Archita Sarmah | Received |
61-MT | Utilizing Single-Use Rhinolaryngoscopes for Fees: A Pre-/Post-Adoption Capability Assessment | Ian Haislip | Received |
61-EPH | Sex-Related Disparities in Chronic Cough Reported by Adults in the United States | Robert Morlock | Received |
61-CO | Discordance Between Apolipoprotein B and LDL-Cholesterol and Incident Hypertension Risk: An Analysis of US Real-World Data | Janna Manjelievskaia | Received |
62-CO | Allogeneic Stem Cell Transplantation Rates and Outcomes in Severe Leukocyte Adhesion Deficiency Type I (LAD-I): A Systematic Literature Review | Heather Ruffino | Received |
62-MSR | Considerations for Censoring Methods Used to Reconstruct Pseudo Patient-Level Data From KaplanMeier Curves | Ioana Gulas | Received |
63-MSR | Prompt Engineering for the Use of Generative Artificial Intelligence (AI) in Health Economic Modeling: Findings From a Targeted Literature Review | Jennifer Benner | Received |
64-CO | Systematic Review of Methimazole in Graves Disease Management: Treatment Variations and Efficacy Outcomes | Kanupriya Mahajan | Received |
65-CO | Indirect Treatment Comparison of Biologic Treatments in Adolescents With Moderate to Severe Atopic Dermatitis: A Systematic Literature Review and Network Meta Analysis | Kevin Li | Received |
65-MSR | Can Low Effective Sample Size in Matching-Adjusted Indirect Comparisons (MAICS) Lead to Bias? Findings From a Simulation Study | Jack Ishak | Received |
65-HTA | Exploring PICO Variations in Relapsed or Refractory DLBCL in the Context of the European Joint Clinical Assessment | Sakshi Jindal | Received |
65-HSD | Optimizing Management and Outcomes of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) in Spain: BEWAYAPDS Project | Kirsten Herrmann | Received |
66-HPR | Readiness Assessment for Cervical Cancer Elimination in Europe | Eugenia Karamousouli | Received |
67-EE | Cost-Effectiveness of Pasireotide Long-Acting Release in Acromegaly: Systematic Literature Review | Grzegorz Binowski | Received |
67-MT | Cost Analysis and Environmental Impact Estimation of Polypropylene Iodine Contrast Media Containers Compared With Glass Containers: A UK Hospital Perspective | Montserrat Chivite | Received |
68-PCR | Preferences in Receiving Clinical Trials Information of Asian, Native Hawaiian, and Pacific Islander Patients With Type 2 Diabetes Mellitus | Tetine Sentell | Received |
68-RWD | Is Individual-Patient Data Essential for Transportability, or Can Aggregated Data Suffice? | Per-Olof Thuresson | Received |
68-EPH | Introduction of a New Dengue Vaccine (TAK-003) in Brazils Public Health System: Impact on Public Health and Cost-Effectiveness Across Different Age Groups | Bruna Mendes da Silva | Received |
69-MT | Next-Generation SequencingBased Circulating Tumor DNA Testing: Clinical Promise Versus Market Access Reality | Jasmine Watson | Received |
70-HSD | Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia in Australian Public Hospitals | mutsa mutowo | Received |
70-MSR | Re-Training of the Artificial Intelligence Tool LiveRefTM: Improved Accuracy and Performance in Data Extraction | Colleen Dumont | Received |
70-HTA | Insights into NICEs Approach to Uncertainties in Health Technology Appraisals | Smruti Panigrahi | Received |
71-HTA | The Acceptance of Using External Data to Inform Survival Extrapolations for Oncology Health Technology Assessments by NICE | Colleen Dumont | Received |
72-HTA | Evolving National Health Technology Assessment (HTA) Frameworks in Theory Versus Practice in the Asia-Pacific (APAC) Region: A Targeted Literature & HTA Review Focusing on Australia, Japan, and Taiwan | Jasmine Watson | Received |
72-RWD | The Association of Hemophilia Related Joint Problems, Healthcare Resource Usage, and Patient Adherence to Prophylactic Treatment: Results From a Multinational Real-World Survey | Sheena Thakkar | Received |
73-MSR | A Framework for Estimating Quality Adjusted Life Years Using Joint Models of Longitudinal and Survival Data | Michael Crowther | Received |
74-HPR | Enhancing the Acceptance of Externally Controlled Trials (ECTs) in the German HTA System: Analysis of Guidance Documents From Other Countries | Jörg Tomeczkowski | Received |
74-PCR | Enhancing Patient-Reported Outcome (PRO) Integration in Early Phase Oncology Trials: Navigating Methodological Challenges and Opportunities | Andrew BOTTOMLEY | Received |
75-HTA | Payer Perceptions of Health Inequalities in Reimbursement Decision-Making: Results of a Global Survey | Tijana Ignjatovic | Received |
76-PCR | Estimating Quality of Life for Systemic Lupus Erythematosus Patients Using aiSLE MGMT: A Smart Disease Management Platform | Eldon Jupe | Received |
76-SA | Systematic Literature Review of the Economic Burden of Hemophilia A and B | Caitlyn Matuska | Received |
76-HSD | Treatment Utilization and Treatment Duration of Patients With Psoriasis Diagnosed With Psoriatic Arthritis in a US Commercial Administrative Claims Database | Jasmine Watson | Received |
77-EE | Optimizing Treatment Pathways for nAMD: Balancing Durability and Costs in the UK | Ivan Rickard | Received |
78-RWD | Coverage and Generalisability of Death Data in the DeSC Database in Japan | Ayumi Hamaguchi | Received |
78-HPR | Opportunities and Barriers for the Implementation of Personalized Medicine in Lithuania | Kornelija Abromaviciute | Received |
79-PCR | Measuring the Caregiver Burden in Children, Adolescents, and Young Adults With Achondroplasia: Results From a Prospective, Cross-Sectional Study | CHRISTINA DUE | Received |
79-MSR | Deploy-AI: A Framework and Future Checklist for Facilitating Deployment of Clinical Prediction Models | Rehan Alice | Received |
80-RWD | Timeline ExplorerIdentifying Time-to-Event Patterns in Real-World Data: An Interactive Open-Source Tool | Bruno Casaes Teixeira | Received |
80-EE | Abelacimab for the Treatment of Stroke Prevention in Atrial Fibrillation (SPAF): An Early Cost-Effectiveness Analysis (CEA) Versus Rivaroxaban from 5 European Country Perspectives | Jennifer Benner | Received |
80-PCR | Barriers and Facilitators to the Recruitment and Engagement of Diverse Populations Into Patient Engagement Groups: A Scoping Review | Colleen Cuthbert | Received |
81-RWD | Characterization of Adult Patients With Myasthenia Gravis Using French Rare Disease Registry | CECILE BLEIN | Received |
81-CO | Pregabalin Utilization and Side Effects Among Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain in US Claims Data | Thilo Schaufler | Received |
82-EE | The Budget Impact of Introducing a Centralized Point of Care Testing Management System in a Hospital in China | xinyue liu | Received |
83-HTA | Assessing Health Technology Assessment (HTA) Outcomes for Conditionally Approved Drugs by the European Medicines Agency (EMA) in Germany, France, and England | Alexandra Guyenet | Received |
83-HPR | Adult Vaccination Financing in the EU and UK: A Comparative Perspective | Karolina Skora | Received |
84-HSD | Towards a Frictionless CAR-T Therapy Process: Identifying and Prioritizing Procedural Preconditions for Oncologic Institutions Using Group Concept Mapping | Ann-Cathrine Froitzheim | Received |
86-PCR | Postnatal Depression: An Underestimated Humanistic Burden in Maternal Health | Jasmine Watson | Received |
86-EPH | Increased Healthcare Resources Utilization and Costs of Long COVID in Community-Managed Adult Patients in France | Jingyan Yang | Received |
87-EE | A Cost-Benefit Analysis on Digitization of Water Treatment Systems in Renal Care Delivery: The Impact on Organizational, Environmental, and Cost Outcomes | Sophie Boeger | Received |
89-CO | Reductions in Concomitant Medication Use and HbA1c Impact Following Initiation of an Advanced Hybrid Closed-Loop System (AHCL) Versus Multiple Daily Injection (MDI) Therapy in People With Type 2 Diabetes (T2D) | Janna Manjelievskaia | Received |
90-EE | Cost-Effectiveness of Caplacizumab for Thrombotic Thrombocitopenic Purpura in Brazil | Julia Simes Correa Galendi | Received |
91-HPR | Price Sensitivity and Uptake of Pharmaceuticals in Sweden and Finland: The Example of New Migraine Drugs | Jenny Wiberg | Received |
91-PCR | Health-Related Quality of Life of Patients With Cushings Disease Treated With Osilodrostat: Mixed-Effects Regression Analysis | Grzegorz Binowski | Received |
92-MSR | Validating the AI Assisted Abstract Screening Feature of Nested Knowledge Platform | Xuan Wang | Received |
92-HTA | NICEs Severity Modifier: Insights From Recent Appraisals | Maisie Borrows | Received |
92-HSD | The Evolution of Single-Use Ureteroscope Use in the United States | Ian Haislip | Received |
93-SA | Inclusion of Deadweight Loss in Healthcare Economic Appraisals | Cillian Copeland | Received |
93-HSD | The Diagnosis and Management of Uncontrolled and Treatment-Resistant Hypertension: A Targeted Literature Review of Eight Countries Clinical Practice Guidelines | James Fotheringham | Received |
94-HPR | Insurance Payments and Hospital Costs Among Patients With S T Segment Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI) in US Hospitals | Gui Lopes | Received |
95-MSR | Health Economic Evaluations Incorporating Broader Perspectives: A Targeted Literature Review | Stacey Chang-Douglass | Received |
95-HTA | Predicting Evidence Requirement Implications of the EU Joint Clinical Assessment (JCA) Through a Population, Comparator, Intervention, Outcome (PICO) Simulation for Two Anticancer Investigational Medicinal Products (IMPs) | Sundeep Ubi | Received |
95-EPH | The Role of Adjuvant Atezolizumab in Reducing Recurrence-Related Treatment Costs in Resected Early-Stage PD-L1 High Non-Small Cell Lung Cancer in Belgium | Liesbet Herteleer | Received |
95-PCR | Performance of the EQ-TIPS and PedsQL in Infants and Toddlers With a Health Condition | Janine Verstraete | Received |
96-HPR | Price Monitoring of Anticancer Drugs Under Price Controlled Category in India | Subhash Mandal | Received |
97-HPR | More Public Funding? A Choice Experiment on the Healthcare Funding System for Older Populations | TAKESHI MORI | Received |
97-CO | Characterizing the Burden and Unmet Need of Antibody-Mediated Rejection | Jasmine Watson | Received |
99-HTA | Matching Insights From Clinical Experts and Generative AI for JCA PICO Validation | Cheryl Jones | Received |
99-EPH | Sepsis Burden in Europes Largest Countries: Hospital-Acquired Cases and Late Diagnosis Impact | Michela Canobbio | Received |
100-EE | Economic Burden of High-Risk Localized and Locally Advanced Prostate Cancer in LATAM: Experts Perspective | Kim Buscemi | Received |
100-HTA | How Do Abbreviated HTA Submissions Impact Reimbursement? A SMC Case Study | Eoin Jennings | Received |
100-RWD | The Impact of COPD Type 2 Inflammation and the Consequences on Outcomes in the Brazilian Private Healthcare System: A Real-World Analysis | Ali Siddiqui | Received |
100-SA | Effect of Adherence to Hemophilia Drug Therapy on Outcomes: A Systematic Literature Review | Caitlyn Matuska | Received |
101-PCR | Patient Characteristics Associated With Treatment Preference for Generalized Myasthenia Gravis (gMG): A Multivariate Analysis | Kristy Maguire | Received |
101-EE | Cost-Effectiveness Analysis of Second-Line Treatment With Lisocabtagene Maraleucel Versus Standard of Care for Patients With Large B-Cell Lymphoma in the Netherlands | Colleen Dumont | Received |
102-SA | Using Retrieval Augmented Generation (RAG) and Agents Workflow for Protocol Authoring | Bruno Casaes Teixeira | Received |
102-EPH | Healthcare Utilization Among RTT Patients With Aspiration and Epilepsy in a Center of Excellence Medical Center in the United States | Nazia Rashid | Received |
103-EPH | Incidence of Solar Retinopathy and Photokeratitis in Private Clinic Post 2017 and 2024 Solar Eclipses Across the USA | Nick Boucher | Received |
103-HSD | Scoping Review on Attitudes and Barriers Towards Therapeutic Drug Monitoring for Biological Treatments for Immune-Mediated Inflammatory Diseases Among Key Stakeholders | Olga Pitsillidou | Received |
103-CO | Characteristics of Patients With Ehlers-Danlos Syndromes (EDS): Analysis of US Real-World Data | Janna Manjelievskaia | Received |
104-HTA | Equity Is Not Equal: A Comparative Study of How Equity Is Considered by NICE, ICER, CDA-AMC, and PBAC | Maisie Borrows | Received |
104-MSR | Applications of Bayesian Borrowing for Assessing Treatment Effects in Clinical Trials | Colleen Dumont | Received |
105-PCR | Impact of CAR T-Cell Therapy on Health Utilities for Patients Diagnosed With Diffuse Large B-Cell Lymphoma in Canada | Lisa Masucci | Received |
105-RWD | Dosing Schedules and Concomitant Medication Usage in Patients With Generalized Myasthenia Gravis Treated With Ravulizumab or Efgartigimod | Kristy Maguire | Received |
105-CO | Impact of Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA) Non-Persistence on Body Mass Index, HBA1C, and Lipids: Analysis of Over 190,000 Adults Treated With Semaglutide, Liraglutide, and Tirzepatide in US Real-World Data | Janna Manjelievskaia | Received |
105-HSD | Treatment Strategies for Uveal Melanoma: A Systematic Review | Rishabh Verma | Received |
106-HSD | Influence of Initial Imaging Type on Time-to-Diagnosis Among Cancers Without Routine Screening Programs: A Seer-Medicare Study | Xiting Cao | Received |
106-HTA | How Has Treatment Switching Been Accounted for? Insights From NICE Appraisals | Jasmine Watson | Received |
107-HPR | The Devil in the Detail: The Challenges of Evaluating Patient Access to Medicines | Jasmine Watson | Received |
108-HTA | Artificial Intelligence Tools for PICO Prediction: A New Reality or a Future Dream? | Paulina Rolska-Wójcik | Received |
108-SA | Clinical and Humanistic Burden of Giant Cell Arteritis and the Associated Unmet Medical Needs: A Targeted Literature Review | Sarah Jane McKenna | Received |
108-HSD | Impact of Predictive Modelling and Application of Preventative Measures in Reducing Fall Rates in Domiciliary Care | Tomas Heger | Received |
110-HSD | Statin Prescribing in Patients With Non-Alcoholic Steatohepatitis in the United States: An Analysis of 3 Real-World Data Sources | Yestle Kim | Received |
111-CO | Indirect Treatment Comparisons of Lefamulin Versus Omadacycline for the Treatment of Community-Acquired Pneumonia | Joanne Wu | Received |
111-SA | Utility of SNOMED CT Vs ICD-10-CM Diagnosis Codes in Identifying Common, Rare, and Ultra-Rare Disease in a Large, Ambulatory Electronic Health Records Database | Janna Manjelievskaia | Received |
112-SA | Machine Learning and Artificial Intelligence for Supporting Systematic Reviews: A Systematic Review of Recent Methodological Developments and Recommendations for Implementation | Caitlyn Matuska | Received |
112-PCR | A Time Trade-Off Study to Develop Health-Related Utility Data for the Impact of Geographic Atrophy on Patients | Michele Intoricia | Received |
113-EE | Follitropin Delta Is Cost-Effective Versus Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France | Marie Markert | Received |
114-HTA | Characterizing Oncology Outcomes in Canadas Drug Agency (CDA-AMC) Reviews From 2022 -2023 | Trisha Whitney | Received |
114-CO | A Systematic Literature Review (SLR) of the Clinical Efficacy and Safety Evidence Associated With Treatments for Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Progressed on Prior Therapies | Shanen Stempel | Received |
114-PCR | Modelling the Benefit of Givinostat on Duchenne Muscular Dystrophy (DMD) Patients, and Their Caregivers | Natalia Arrabal | Received |
116-MSR | Artificial Intelligence (AI)-Assisted Early Data Insights and Literature Monitoring: A Case Study of Maintaining an Up-to-Date Reference Library in Metastatic Prostate Cancer (MPC) | Colleen Dumont | Received |
117-PCR | Health State Utility Values for Sleep Disturbance and Early Morning Off Symptoms in Advanced Parkinsons Disease: A Vignette-Based Approach Using the EQ-5D | Pablo Arija Prieto | Received |
118-PCR | Impact of SHE Frequency and IAH Status on Sleep Quality in Adult Continuous Glucose Monitor Users With Type 1 Diabetes: Results From a Cross-Sectional Survey Study | Zara Petzoldt | Received |
118-CO | Indirect Treatment Comparison (ITC) of Avalglucosidase Alfa (AVA) vs Cipaglucosidase Alfa Plus Miglustat (Cipamig) in Late-Onset Pompe Disease (LOPD): An Updated Analysis Using Mixed-Model Repeated Measures (MMRM) Data | Mau Sinha | Received |
118-RWD | Rare-Xtract: A Hybrid Pipeline for Generating Real-World Data Products From Unstructured Electronic Medical Records (EMRs) of Rare Diseases Leveraging Natural Language Processing (NLP) and Keyword Extraction Techniques | Alva James | Received |
119-CO | Methodological Considerations for Time-to-Event Analyses of Non-Interventional Studies (NIS) Collecting Real-World Data (RWD) Prospectively: A Simulation Study | Hamid Mahmoudpour | Received |
120-RWD | Leveraging the DeSC Database for Alzheimers Disease Research in an Aging Population in a Real-world Setting in Japan | Ayumi Hamaguchi | Received |
120-MSR | Quantifying Health Related Quality of Life Benefits From Patients Treated With Mavacamten for Obstructive Hypertrophic Cardiomyopathy (HCM) in China Based on the EXPLORER-CN Trial | JIA YU | Received |
120-EE | Factors Associated With the Inclusion of Societal Costs in Published Cost-Effectiveness Analyses, 2013-2022 | Meng Li | Received |
120-HTA | Interpreting the Non-Inferiority Evidence in NICE Streamlined Cost-Comparison Appraisals | Carina Marie Behr | Received |
121-HTA | Improving Literature Review Efficiency: Evaluating the Impact of the Opensource Asreview Tool on Time and Effort to Conduct Systematic and Targeted Reviews | Nicole Tunstall | Received |
121-PCR | Can You Feel the Tension? Evaluating the Translatability of Complex Terminology in PROs | Tim Poepsel | Received |
121-SA | Can Living Systematic Literature Reviews Reduce Research Wastage? An Evaluation of LiveSLR | Colleen Dumont | Received |
122-EPH | Understanding the Patient Journey of Lung Cancer Patients in China: A Multi-Center Study | Sean Kao | Received |
125-RWD | Identifying Fit-for-Emulation Data: Adaptation of a Structured Data Feasibility Assessment Process for Real-World Oncology Trial Emulations | Adina Estrin | Received |
125-PCR | Assessing the Relationship Between EQ-5D-3L Index Scores and Disease-Specific Patient-Reported Outcome Measures in Eosinophilic Oesophagitis | Ali Siddiqui | Received |
125-EE | Cost-Effectiveness of Targeted Newborn Screening for Congenital Cytomegalovirus Infection in Japan | MOTOKO TANAKA | Received |
125-EPH | How Do We Refer to Individuals in the Scientific Literature? Use of Person-First Language vs Condition-First Language in Oncology Medical Journals | Agnes Williams | Received |
126-RWD | Clinical Characteristics and Frailty of Patients With Mild Cognitive Impairment or Dementia Due to Alzheimers Disease: A Real-World Survey | Diego Novick | Received |
127-PCR | Persons With Dementia From a Migration Background and Informal Caregivers Prioritizing Their Aging-in-Place Care Preferences: A Mixed Methods Study | Soukaina el Jaouhari | Received |
127-EE | Economic Evidence Associated With Treatments for Patients With Non-Small Cell Lung Cancer (NSCLC) Who Progressed on Prior Therapies: A Systematic Literature Review (SLR) | Shanen Stempel | Received |
128-PCR | Health-Related Quality of Life of Patients With Charcot-Marie-Tooth Disease: A Systematic Review | Sukannya Mahapatra | Received |
128-RWD | A Real-World Data Landscape Review of the 2023 International Society for Pharmacoeconomics and Outcomes Research Europe Conference | Deb Casso | Received |
129-HPR | An Umbrella Review of the Impacts of Climate Change on Maternal Health and Birth Outcomes | Colleen Dumont | Received |
130-PCR | Health-State Utility Values and Their Time to Deterioration in Informal Caregivers of Elderly Patients With Chronic Diseases | Taha JAI | Received |
130-CO | Outcomes and Economic Effects of Digital Health Services: An Umbrella Review | Elina Laukka | Received |
130-HTA | Key Drivers Underlying Positive and Negative Decisions for National Institute for Health and Care Excellence (NICE) Technology Appraisals (TAS) and Highly Specialised Technology (HST) Appraisals in 2023 | Michael Tang | Received |
131-EE | Systematic Review of Cost-Effectiveness Modelling Studies for Haemophilia | Niklaus Meier | Received |
131-CO | Comparative Efficacy of Elafibranor and Seladelpar in Patients With Primary Biliary Cholangitis: A Network Meta-Analysis | Shimaila Siddiqui | Received |
131-MSR | Effective Outcome Measures for Family Caregivers of Patients With Alzhemers Disease in Japan: Conducting Factor Analysis Using ASCOT-Carer, ZBI, and EQ-5D-5L | Tomohiro Kondo | Received |
132-EPH | Inadequate Response to Therapy Among Ulcerative Colitis Patients Initiating an Advanced Therapy: A Retrospective Analysis of German Health Claims Data | Carolina Schwedhelm | Received |
133-EE | Cost-Effectiveness of Intensive and Local Neonatal Care Units in England: A Real-World Evidence Analysis of a National Birth Cohort | Oliver Rivero-Arias | Received |
133-HPR | The Global Impact of EU HTA: Insights From 13 Non-EU Countries | Maria João Garcia | Received |
136-MSR | Feasibility of GPT-4-based Content Extraction to Identify Eligible Titles and Abstracts in a Systematic Literature Review | Lalith Mittal | Received |
136-CO | Chemoimmunotherapy With Dinutuximab Beta Compared to Chemotherapy Regimens in Patients With Relapsed/Refractory Neuroblastoma: Systematic Literature Review and Indirect Treatment Comparison | Grzegorz Binowski | Received |
137-MSR | The Impact of Censoring Assumptions on STC-Adjusted Simulated Time-to-Event Data | Colleen Dumont | Received |
137-HPR | Evaluating the Clinical and Socioeconomic Impact of Improved CKD Diagnosis and Adherence to Guideline-Directed Medical Therapy in Australia, Brazil, and China: An Impact CKD Analysis | Trisha Whitney | Received |
137-HSD | The Value Proposition of Remote Monitoring in Heart Failure: Pains and Gains Towards Patients Adoption | Robert Menkveld | Received |
138-PCR | Inequalities in the Impact of Dermatological Diseases Across the Globe: Impact Results From the GRIDD Study | Allison FitzGerald | Received |
139-EPH | Prevalence and Disease Burden of Disease-Related Malnutrition in Hospitalized Patients in Spain | Esteban Lifschitz | Received |
139-RWD | Characteristics of Ovarian Cancer Patients: A Real-World Perspective for 1st Line Maintenance Treatment Choice After 1st Line Platinum Based Induction Therapy Across EU4 & UK | Karina Palhares | Received |
142-EE | Alectinib, Brigatinib, and Lorlatinib As First-Line Therapies for Advanced ALK-Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis | Rahul Mudumba | Received |
143-RWD | Caregiver Burden Among Patients With COVID-19: A Systematic Literature Review of Real-World Evidence | Shailja Vaghela | Received |
144-MSR | Group-Based Trajectory Modelling Considerations: Learnings from a Published Application in Acute Myeloid Leukaemia | Emily Aiello | Received |
144-EE | The Budget Impact of Cangrelor for the Treatment of Patients With Gastric Absorption Issues Undergoing Percutaneous Coronary Intervention in the UK | richard stork | Received |
145-HTA | Qualitative and Quantitative Evidence Synthesis Strategies to Support JCA and IRA Submissions | Caitlyn Matuska | Received |
145-EE | Evaluating the Cost-Efficacy of Calcipotriol Plus Betamethasone Dipropionate Cutaneous Pad Cream for the Topical Treatment of Mild to Moderate Plaque Psoriasis in Italy | Rituparna Banerjee | Received |
145-PCR | Evaluating the Impact of the Cionic Neural Sleeve on Quality of Life in Multiple Sclerosis Patients: A Pilot Study | Bruce Wang | Received |
146-MSR | Deriving an Analytical Solution to Inversion of Royston/Parmar Restricted Cubic Spline Parametric Survival Models for Discrete Event Simulation | George Bungey | Received |
146-EPH | Progression to Metastatic Breast Cancer According to Stage and Biomarker Status at Diagnosis in Denmark: A Register-Based Cohort Study | Jenny Wiberg | Received |
147-RWD | Development of a US-Based, Real-World, Ophthalmology Registry Based on Automated EHR Data Extraction to Support Opportunities for Clinical and Health Economics and Outcomes Research in Eyecare | Nick Boucher | Received |
149-PCR | Burden of Childhood Arthritis: Work Productivity Loss and Activity Impairment of Parents and Caregivers | Deborah Marshall | Received |
150-RWD | First Patient Enrolled in Pilot Phase of the Economics and Patient Outcomes in China in Hemophilia (EPOCH) Study | Elizabeth Clearfield | Received |
151-CO | Overall Survival of Patients With Large B Cell Lymphomas in Poland After Chimeric Antigen Receptor T Cell (CAR-T) Therapies Compared to the Real-World Evidence From Other Countries | Grzegorz Binowski | Received |
152-CO | Simulation of Long-Term Impact of Bempedoic Acid and Ezetimibe on Atherosclerotic Cardiovascular Disease Outcomes in Europe | Caitlyn Matuska | Received |
153-HTA | Health Equity Priorities for Pharmaceutical Manufacturers: Payer Perceptions From a Global Survey | Tijana Ignjatovic | Received |
156-HTA | Assessing the Generalizability of Automating Adaptation of Excel-Based Cost-Effectiveness Models Using Generative AI | Cheryl Jones | Received |
157-RWD | A Real-World Study of Multiple Myeloma Patients With at Least 3 Prior Treatment Lines and Triple Class Exposed Disease in Finland: Outcomes and Need for Healthcare Resource Use | Akseli Kivioja | Received |
157-EE | Economic Burden of Charcot-Marie-Tooth Disease: A Systematic Review | Sukannya Mahapatra | Received |
157-CO | Carfilzomib in Combination With Dexamethasone and Daratumumab (KdD) Versus Carfilzomib in Combination With Lenalidomide and Dexamethasone (KRd) in Relapsed and/or Refractory Multiple Myeloma: An Indirect Treatment Comparison | Sachin Patel | Received |
158-PCR | Attribute Development and Level Selection for a Discrete Choice Experiment to Elicit Care Preferences of Older Adults and Informal Caregivers Aging in Place in the Netherlands | Isabelle Vullings | Received |
159-EE | Cost-Effectiveness of the Personalization of Immunosuppressive Therapy in Kidney Transplantation by Means of an in Vitro Diagnostic Test (IMMUNOBIOGRAM) in Spain | Maria Teresa Diez Laplaza | Received |
159-EPH | Estimating the Remaining Chronic HCV Prevalence in Ireland: A Risk Population Modelled Approach Applied in Practice | Nic Talbot-Watt | Received |
160-HPR | Integrating Healthcare System Value Into New Medicine Evaluations for Timely and Full Patient Access | Jasmine Watson | Received |
161-CO | Use of Generative AI for Rapid and Accurate Extraction of PICOs at Scale | Diana Steinway | Received |
162-CO | A Systematic Literature Review to Assess the Variability in Conducting and Reporting of Matching-Adjusted Indirect Comparisons in Chronic Lymphocytic Leukemia: Findings and Implications for EU HTA | Varun Ektare | Received |
164-EPH | Clinical and Economic Burden of Obesity Among Hospitalized Patients in the United States | Gui Lopes | Received |
164-PCR | Worldwide Longitudinal Observational Study of Fatigue-Related Symptoms in Patients With Relapsing Multiple Sclerosis, Daily Assessment and 7-Day Lookback | Gilda Teissier | Received |
166-PCR | Exploring the Content Validity of the EQ-5D-5L and Four Bolt-Ons (Skin Irritation, Self Confidence, Sleep, Social Relationships) in Atopic Dermatitis and Chronic Urticaria | Katy Gallop | Received |
169-MSR | Health Technology Decision-Making in an Imperfect World: A Unifying Framework of Value of Information and Implementation Metrics Based on a Narrative Review | Sabine Grimm | Received |
170-PCR | A Systematic Scoping Literature Review to Identify the Humanistic Burden Attributed to Living With Primary Sjogrens Disease | Zlatko Boni | Received |
170-EPH | Burden of Severe ANCA Associated Vasculitis in Australia via Real-World Usage of Rituximab | Scott Brydon | Received |
171-RWD | Leveraging Artificial Intelligence to Enhance the Quality and Efficiency of Real-World Evidence Generation in HEOR | Thibaut Vergnol | Received |
171-HPR | Estimating the Impacts of Government-Mandated Price Reductions on Indication Expansion for Launched Drugs: A Real-World Study | Jacqueline Rhuda | Received |
172-CO | Characterizing the Burden and Unmet Need of Lupus Nephritis | Jasmine Watson | Received |
172-RWD | Optimizing RWE Design and Conduct by Leveraging Computable Operational Definitions Indication Libraries: Development, Verification, and Value | Jared Kamauu | Received |
172-EPH | Unmet Needs and Spatiotemporal Variation in Vitiligo: A Retrospective Longitudinal Web Search Analysis | Michael Hindelang | Received |
173-PCR | The Geographic Atrophy Long-Term Outcomes Study (GALTOS): Preliminary Analysis of Patient Clinical Characteristics, Retrospective Natural History, and Patient Survey Results | Michele Intorcia | Received |
174-EE | Societal Impact Valuation of Axicabtagene Ciloleucel in Diffuse B-Cell Lymphoma in the Netherlands | Angela Borghouts- de Ruijter | Received |
174-PCR | Importance of Specific Clinical Trial Enrollment Strategies for Native Hawaiian, Pacific Islander, and Asian Patients With Type 2 Diabetes Mellitus | Deborah Taira | Received |
175-CO | Clinical Outcomes of Interventions in Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Systematic Literature Review | Isabelle Lundqvist | Received |
176-HTA | Assessing Trends in European Unions Health Technology Assessment Submissions of Antibody-Drug Conjugates | Debjit Ghoshal | Received |
177-EPH | A Multimodal Deep Neural Network for Early Prediction and Detection of Alzheimers Disease Based on MRI Images and Clinical Information | Xinyao Yi | Received |
177-HPR | Modeled Impact of Risk-Sharing Agreements on Costs for Hemophilia B Gene Therapy in Germany | Lasse Falk | Received |
178-HPR | Quantifying Health Inequity: An Umbrella Review of Systematic Literature Reviews on Sex-Based Differences in Health Outcomes | Colleen Dumont | Received |
179-HTA | A Targeted Review of Treatment Beyond Progression in NICE HTA Oncology Submissions | Colleen Dumont | Received |
179-MSR | Automated Extraction of Cost-Effectiveness Models Data from Health Technology Assessment Submissions Using Large-Language Models (LLMS): Does the Prompting Approach Matter ? | Simone Rivolo | Received |
180-PCR | Patterns in Attribute Selection Reporting in Patient Preference Studies: A Systematic Review | Rebekah Hall | Received |
180-MSR | Challenges in NMA Methodology Based on Re-Randomization vs Treat-through Trial Designs | Susanne Hartz | Received |
181-PCR | Quality of Life and Its Drivers in Patients With Uveal Melanoma: A Systematic Review | Rishabh Verma | Received |
182-PCR | Underestimation of the Burden of Gout | Robert Morlock | Received |
182-HTA | Evaluating the Use, Performance, and Acceptability of Utility Measurement Approaches in Geographic Atrophy: A Severe Vision Disorder | Emma Williams | Received |
183-RWD | How Does Real-World Evidence Support Regulatory and HTA Agency Assessments and Beyond? | Jasmine Watson | Received |
184-PCR | Comparing the Humanistic and Economic Impact of Osteogenesis Imperfecta Affected and Non-Affected Caregivers, When Caring for an Individual With Osteogenesis Imperfecta | Heather Muhall | Received |
185-EE | Assessing the Economic Impact of the Adoption of Digital Single-Use Cholangioscopes for the Treatment of Choledocholithiasis During Laparoscopic Cholecystectomy: A Health Economic Model for Spanish Hospitals | Oleksandr Topachevskyi | Received |
185-CO | Gene Therapies for High-Grade Gliomas and Glioblastomas: A Systematic Review | Stacey Chang-Douglass | Received |
186-HPR | Developing a Value Framework to Determine New Drugs Price Premium Using Multi-Criteria Decision Analysis Approach: SFDA Experience | Mona Almaghrabi | Received |
187-MSR | Automated Data Extraction in Systematic Literature Reviews (SLRs): Assessing the Accuracy and Reliability of a Large Language Model (LLM) | Carolina Casañas i Comabella | Received |
187-HPR | Injectable Oncology Therapies: Benchmarking Gross and Net Price Differentials in Europe vs US | Nekshan Dalal | Received |
187-PCR | EQ Health and Wellbeing (EQ-HWB): Assessing the Distinctiveness of Frequency and Severity Response Scales in Measuring Pain and Discomfort | Soumana Chamoun Nasser | Received |
188-RWD | Unlocking the Potential of Interoperable Linked Low-Latency National Health Data in England to Protect Vulnerable Patients While Safeguarding Their Privacy: A Brave New World | ss ss | Received |
189-HPR | To What Extent Are Oncology Submissions to the National Institute for Health and Care Excellence (NICE) Incorporating a Probabilistic Base Case? | Colleen Dumont | Received |
189-EE | Hospitalizations in Patients Receiving Durvalumab Plus PlatinumEtoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: Exploratory Analysis From the Phase IIIb CANTABRICO Study | Anisia Martinez | Received |
191-RWD | Real-World Medical Utilization and Outcomes Associated With Treatments for Advanced ALK-Positive Non-Small Cell Lung Cancer | Rahul Mudumba | Received |
191-PCR | Counting on Data Validity in Multinational Clinical Trials? Numeral Systems in Patient-Reported Outcome Assessments: Guidance for Linguistic Validation | Tim Poepsel | Received |
191-CO | Application of Causal Inference Methods to Assess Efficacy in Secondary Outcomes in Ophthalmology Clinical Trials for Use in Economic Models | Michele Intoricia | Received |
192-PCR | Quality of Life and Its Drivers for Patients Living With Angelman Syndrome (AS): A Systematic Review | Vyshnavi Telukuntla | Received |
193-RWD | Heterogeneity in Crohns Disease and Ulcerative Colitis Clinical Endpoints Leading to Uncertainties in the Real-World Setting | Sabera Hashim | Received |
193-CO | Risk Factors Associated With an Aspiration Outcome in Patients With Rett Syndrome: Analysis of Real-World Data in the United States | Nazia Rashid | Received |
194-EPH | Estimating the Prevalence of Controversial Denials of Essential Medicines and Health Services Through Legal Case Review | Emily Kelty | Received |
194-PCR | Using Distribution-Based Methods to Determine Minimal Important Differences With the Hypoglycemia Fear Survey-II in Adults With Type 1 Diabetes | Zara Petzoldt | Received |
194-HTA | Overview of NICE Cost-Comparison Technology Appraisals: Key Takeaways Regarding Comparator Selection and Methods Used to Demonstrate Comparable Efficacy | Jake Astill | Received |
196-CO | Efficacy of Treatments for Pediatric Patients With Relapsed/Refractory High-Grade Glioma: Results From a Systematic Review of the Literature | rachid rafia | Received |
197-HTA | Recent Trends From UKs Cancer Drugs Fund, Key Drivers of Acceptance | Jasmine Watson | Received |
199-HPR | Impact of the Innovative Licensing and Access Pathway (ILAP) Designation on Regulatory and Health Technology Assessment (HTA) Outcomes | Caitlyn Matuska | Received |
199-EPH | Health Impact and Burden of Illness in Immune Thrombocytopenia: A Literature Review on Clinical, Humanistic, and Economic Burden | isabelle lundqvist | Received |
200-EE | A Comparison of Outcomes Measures in Cost-Effectiveness Analysis: Three Applications Within Oncology | Brian Reddy | Received |
203-MSR | Using Machine Learning to Explore Scientific and Social Media Engagement With Medical Publications | Helen Stewart | Received |
204-MSR | Exploration of AI-Tools Used in Systematic Reviews and Evidence Synthesis | Immaculate Nevis | Received |
206-EE | Estimation of the Health and Economic Effects of Innovations in Health Care at a Societal Level | Guillaume Moukala Same | Received |
206-HPR | Evaluating the Maturity Level of Health Technology Assessment in Latin America: A Comparative Qualitative Analysis | Bruno Boietti | Received |
207-HPR | How Long Is Long Enough? Data Collection Duration for Medicines in Managed Access in England | Charlotte Bee | Received |
208-EE | Stakeholder Views on the Use and Challenges of Using Economic Evaluations in Health Innovation Development in the Netherlands | Chris van Lieshout | Received |
210-EE | Hospitalization Costs of Common Grade 3/4 Adverse Events Associated With Oncology Treatments in the United States: 2024 Update | Caitlyn Matuska | Received |
212-EPH | Prevalence of Pulmonary Embolism Among Medicare Enrollees: A Six-Year Perspective | Luckyboy Vang | Received |
214-HTA | Trends Underlying Positive and Negative Decision-Making for New Treatments Targeting Rare Diseases (RD) Appraised by the National Institute for Health and Care Excellence (NICE) in 2023 | Michael Tang | Received |
215-HTA | Targeted Review: Generalizability of Clinical Trial Evidence to the Patient Population in NICE Technology Appraisals | Isobel Thornton | Received |
215-PCR | PRO Gap Analysis in Antibody Mediated Rejection, Delayed Graft Function, Lupus Nephritis, and Membranous Nephropathy | Jasmine Watson | Received |
219-HTA | Transporting Real-World Evidence: Is It Possible to Transport OS Estimates in HER2 mBC From US to UK? | Darren Johnson | Received |
219-MSR | Can Artificial Intelligence (AI) Accurately Screen Abstracts in Systematic Literature Reviews? | Noemi Hummel | Received |
220-HTA | AI-Assisted Review of NICE Guidance for Highly Specialized Technologies: Economic Modelling of Ultra-Rare Conditions | Stacey Chang-Douglass | Received |
221-HPR | Revisiting Healthcare Resource Allocation for Immunotherapeutic Treatments in Cancer | Hamideh Mahdiani | Received |
221-EE | The Willingness to Pay Threshold in the Netherlands: Time for an Update! | Angela Borghouts- de Ruijter | Received |
224-HPR | Utilization of Long-Term Care Before and After the 2015 Dutch National Reform: An Interrupted Time Series Analysis | Janet MacNeil Vroomen | Received |
224-HTA | A Roadmap to the Use of Value of Information Analysis in Health Technology Assessment: An International Study of Barriers, Facilitators, and Potential Applications | Sabine Grimm | Received |
225-EE | Burden of Chronic Obstructive Pulmonary Disease (COPD) Healthcare Costs in Patients with Moderate-to-Severe Disease | Ali Siddiqui | Received |
227-PCR | A Real-World Longitudinal Study Characterizing the Impact of Fatigue in Adults With Relapsing Multiple Sclerosis | Gilda Teissier | Received |
230-EPH | Geographic Variation in Routine Childhood Vaccination Using Real-World Evidence: Pre- and Post- COVID-19 Pandemic | Jasmine Watson | Received |
231-MSR | Searching Clinical Trial Registries in Systematic Literature Reviews (SLR): Which and Why? | Lalith Mittal | Received |
232-HPR | Eurocover-CLL: Reimbursement and Accessibility for New Treatments in Relapsed/Refractory Chronic Lymphocytic Leukemia in Central and Eastern Europe | Magdalena Monica | Received |
237-PCR | Patient Activation and Health Outcomes in Spinal Surgery: A Systematic Literature Review of Measures, Effects, and Strategies | Mehdi Zahra | Received |
239-PCR | Comparative EQ-5D Utilities for Valoctocogene Roxaparvovec Gene Therapy and Emicizumab in People With Severe Hemophilia A Using a Matching-Adjusted Indirect Comparison | Milad Karimi | Received |
239-EPH | Positive Airway Pressure (PAP) Therapy in Obstructive Sleep Apnea (OSA): Modeling of 20 Year Mortality and Hospitalizations | Ankit Ghildiyal | Received |
241-EE | Fondaparinux: A Cost-Saving Alternative to Low-Molecular-Weight Heparins for Venous Thromboembolic Event Prevention/Treatment and Acute Coronary Syndrome Treatment | Henning Austrup | Received |
242-HPR | Lump-Sum Envelopes: High Predictability for Payers (Healthcare Product Pricing Committee CEPS) and Minor Contribution for Companies | Philippine Poignant | Received |
243-HTA | Mixture Cure Model in HTA Submissions: A Comparative Review | Yan Zhi Tan | Received |
244-HPR | Innovative Reimbursement Agreements Addressing the Challenges of Advanced Therapy Medicinal Products: Systematic Review for the Five Major European Healthcare Systems (EU5) | Roman Spelsberg | Received |
245-EE | Economic Burden in Patients With Chronic Myeloid Leukemia in Early Lines of Therapy: A Literature Review | Isabelle Lundqvist | Received |
248-EPH | Age-Adjusted Years of Potential Life Lost (YPLL) Rates Due to Ovarian Cancer in Chile During 2002-2019 | Abbas Ali | Received |
249-PCR | Use of Digital Methods to Collect Real-World Data in Participants With Psoriatic Arthritis Treated With the IL-23 Inhibitor Guselkumab or IL-17 Inhibitors: Baseline Characteristics From the eDaily PsABIond Sub-Study | Fiona Allum | Received |
253-PCR | Visualizing Risk: Risk Graphics Impact on Patient Understanding and Choices in Preference Studies | Stella Marceta | Received |
259-PCR | Life and Work Productivity Impairment in Adult Continuous Glucose Monitor Users With Type 1 Diabetes: Results From a Cross-Sectional Survey Study | Zara Petzoldt | Received |
261-EE | Economic Evaluation of Dupilumab Versus Standard of Care for the Treatment of Adult Patients With Moderate-to-Severe Prurigo Nodularis in the United States | Caitlyn Matuska | Received |
262-EE | Cost-Consequence Analysis of Cabozantinib in Combination With Nivolumab in Treatment of First-Line Advanced Renal Cell Carcinoma in Germany: A Payer Perspective | Julia Stiefel | Received |
266-PCR | Saliency Versus Ranking: Exploring the Utility of Tasks Used in Qualitative Research to Identify Concepts That Are Most Important to Patients | Catherine Bottomley | Received |
268-HTA | Exploring Potential: Performing Multi-Criteria Decision Analysis (MCDA) on Orphan Drugs in the Dutch Context | Ellen Anna Kok | Received |
268-EE | Interim Burden of Disease Findings for Myasthenic Gravis-Resource Utilization Epidemiology, Survival, and Treatment Patterns (MG-REST) Study in Ontario, Canada | Kobina Quansah | Received |
268-EPH | Private market uptake of varicella vaccination and related sociodemographic differences: A Danish nationwide observational study | Mette Boie Steffensen | Received |
271-PCR | Mindful Measures: Assessing Content Validity of Patient-Reported Outcomes for Major Depressive Disorder in Clinical Trials | Daniella Olonilua | Received |
275-EPH | Treatment Patterns and Patients Pathways in Actinic Keratosis Population: A Retrospective Longitudinal Cohort Study in the French National Health Insurance Claim Database (SNDS)EPIKA Study | Adam DOBLE | Received |
277-PCR | Patients Perspective of the Access to and Quality of Care for Chronic Kidney Disease: Insights From the DISCOVER-CKD Qualitative Study | Ewelina Palmer | Received |
277-EE | Cost of Stroke in Latin America: A Multicentric Time-Driven Activity-Based Costing Study | Luiza Dittrich | Received |
282-HTA | The NICE QALY Severity Modifier: What Have We Learned So Far | Jasmine Watson | Received |
283-PCR | Through Their Eyes: Defining Good Life in Dementia for Health Economics Outcome Measures | Irina Kinchin | Received |
283-EE | Number of Needed to Treat (NNT) to Achieve Seizures Reduction or Seizure Freedom in Dravet Syndrome in France: Results From an Itc of Stiripentol vs Fenfluramine and Cannabidiol and the Economic Implications | Marie Fourcroy | Received |
285-PCR | Quality of Life in Early-Stage Chronic Kidney Disease: A Targeted Literature Review | Amit Ahuja | Received |
286-PCR | Targeted Literature Review to Explore the Patient Experience of Hemolytic Disease of the Foetus and Newborn (HDFN) | Jennifer Norma Barthelmes | Received |
288-EPH | Characteristics of NASH Patients Who Develop Hepatocellular Carcinoma (HCC) With and Without a Corresponding Cirrhosis Diagnosis | Yestle Kim | Received |
289-EPH | Effect of Anti-Rheumatic Drugs on Diabetic Foot Disease Among Patients With Type 2 Diabetes and Rheumatoid Arthritis | Zhaonan Wang | Received |
290-PCR | Characterizing Fatigue in US, European, and Latin-American Adults With Relapsing Multiple Sclerosis: A Real-World Study Conducted Using a Novel Disease Specific Scale | Teissier Gilda | Received |
291-EE | Integrating a Markov Chain Monte Carlo Convergence Diagnostics Output Analysis (CODA) Into State Transition Cost-Effectiveness Models in Microsoft Excel: A Stepwise Approach | Colleen Dumont | Received |
292-EE | Cost-Effectiveness Analysis of PCV20 31 Versus PCV15 21 Vaccination of the Pediatric Population in the Netherlands | Michel Peters | Received |
293-EE | Cost-Effectiveness of Diagnostic Testing for Hepatitis Delta in the United Kingdom | Mirko von Hein | Received |
302-HTA | Consideration of Societal and Equity-Based Value Attributes (VAs) by the National Institute for Health and Care Excellence (NICE) During Evaluation of Innovative Technologies in 2023 | Michael Tang | Received |
304-HTA | Is the New EU HTA Process Fit for Engagement of Patients With Rare Diseases? | Gavin Outteridge | Received |
305-HTA | Development of a Stepwise Approach to Assessing the Feasibility of Conducting a Distributional Cost-Effectiveness Analysis | Maisie Borrows | Received |
306-EE | Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses | Paulina Kazmierska | Received |
306-PCR | Exploring the Difference That Patient Involvement in HTA Makes in Cancer | Peter Wagner | Received |
307-EE | Comparing Ancillary Services Associated With Subcutaneous Versus Intravenous Medication Administration | Phillip Sarocco | Received |
311-EE | Evaluating the Cost-Effectiveness of Ruxolitinib for the Treatment of Polycythaemia Vera Patients That Are Resistant/Intolerant to Hydroxycarbamide/Hydroxyurea in England and Wales | rachid rafia | Received |
315-PCR | Labeling Risk: Comparing Occurrence vs Severity-Based Risk Labels in Patient Preference Studies | Stella Marceta | Received |
316-PCR | Utility Values for Endoscopy and Symptoms-Based Health States in Crohns Disease: Analysis of Data From a Phase 3 Randomized Controlled Clinical Trial | Susanne Hartz | Received |
318-PCR | Unmet Needs of Patients With Severe Von Willebrand Disease and Their Caregivers: A Qualitative Study on Current Standard of Care in Canada | Tiffany Cristarella | Received |
320-HTA | How to Manage the Multiple PICOs and Challenging Timelines in Systematic Reviews for JCA Submissions | SOHAN DESHPANDE | Received |
320-PCR | Real-World Quantitative Insights of Cancer Patient Experience With Subcutaneous (SC) Vs Intravenous (IV) Drug Delivery | Phillip Sarocco | Received |
325-HTA | Stakeholder Perspectives on the Draft Implementation Act for Joint Clinical Assessments: Key Insights and Concerns | Trisha Whitney | Received |
336-EE | Real-World US Optum Claims Database Study of Pre- and Post-Relapse Costs and Health Care Resource Utilization (HCRU) in Patients With High-Risk Localized or Locally Advanced Prostate Cancer (HR-LPC/LAPC) Who Relapsed | Kim Buscemi | Received |
336-HTA | Evaluation of Rejected Reimbursement Decisions in NICE and CADTH Submissions for Non-Small Cell Lung Cancer | Colleen Dumont | Received |
337-EE | Cost-Effectiveness of 177LuLu-PSMA-617 in Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | Caitlyn Matuska | Received |
339-EE | Cost and Healthcare Resource Utilization (HRU) Among Patients Living with Angelman Syndrome (AS): A Systematic Review | Vyshnavi telukuntla | Received |
342-EE | The Budget Impact of Introducing an Arterial Blood Gas Syringe With or Without an Automatic Blood Gas Analyzers in Intensive Care Unit in China | xinyue liu | Received |
343-HTA | Reduced Access to Pharmaceuticals in the Nordics: Can It be Explained? | Jenny Wiberg | Received |
343-EE | Cost-Effectiveness Analysis of Resmetirom for the Treatment of Adults With Noncirrhotic NASH and Moderate-to-Advanced Liver Fibrosis in the US: Integrating the Dual NASH Resolution and Fibrosis Improvement Endpoints | Yestle Kim | Received |
348-HTA | Development and Proof-of-Concept Study of a Life-Cycle Prioritization Framework for Oncology Product Innovation | Deirdre Weymann | Received |
348-EE | Number Needed to Treat and Cost-per-Responder Analysis of Dupilumab and Mepolizumab in Chronic Rhinosinusitis With Nasal Polyps | G Kaushik Subramanian | Received |
352-EE | Cost-Effectiveness of Chikungunya Vaccination With IXCHIQ in Adults in Puerto Rico | Adrianne de Roo | Received |
352-HTA | The Benefits and Challenges of Streamlined NICE Cost Comparisons | Carina Marie Behr | Received |
353-HTA | Developing Economic Evaluation Guidelines for Saudi Arabia Local Experts Engagement | Fatma Maraiki | Received |
358-HTA | Access to Innovative Therapies in Rare DiseasesEvaluation Challenges of Single Arm Trials With External Control Arm: FDA Versus French Has Evaluations Between 2018 and 2024 | Haifa BEN ROMDHANE | Received |
360-HTA | Acceptability of Real-World Evidence by European HTA bodies to Support Value Assessments of Rare Disease Therapies | Richard Massey | Received |
365-EE | Economic Evaluation of Transcatheter Aortic Valve Implantation (TAVI) Relative to Other Interventions in Cardiovascular and Oncology Disease Areas: A Targeted Literature Review | Archita Sarmah | Received |
366-HTA | Challenges and Criteria for Accepting Lower-Level of Evidence in Early Benefit Assessments (EBA) in Germany | Jörg Tomeczkowski | Received |
367-EE | Health Care Resource Utilization and Costs Among Patients With Severe Hypertriglyceridemia and Acute Pancreatitis or Major Adverse Cardiovascular Events | Susannah Hershberg | Received |
368-EE | Angiotensin II (ANGII) Reduces Intensive Care Unit (ICU) Length of Stay Providing Cost Savings in the Treatment of Refractory Distributive Shock (DS) | Attila Mihalik | Received |
374-EE | Transcatheter Aortic Valve Implantation vs Surgery in Symptomatic Severe Aortic Stenosis Patients at Low Surgical Mortality Risk in Belgium: An Updated Cost-Utility Analysis Based on the 5-Year Data From the Partner 3 Trial | Archita Sarmah | Received |
378-EE | Health Economic Impact of Maternal Bivalent Stabilized Prefusion F Subunit Vaccine for Prevention of Respiratory Syncytial Virus Infections Among Infants in Germany | Ahuva Averin | Received |
380-EE | A Case Study of Real-World Health Resource Utilization and Costs in a Patient With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), an Ultra-Rare Pediatric Disease | Charlotte Camp | Received |
381-HTA | Using Artificial Intelligence (AI) to Extract National Institute for Health and Care Excellence (NICE) Final Appraisal Documents (FAD): Evaluating the Potential Application of Large Language Models (LLM) vs Human Extraction | Michael Tang | Received |
385-HTA | Psychological Aspects of Payer Decision-Making in Healthcare: Which Attitude Components Drive Decisions and How Can These Be Influenced? | Lucy Nelson | Received |
386-EE | Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against Il-17A, Il-12/23 and Il-23 Inhibitors for the Treatment of Psoriatic Arthritis in Finland | Jenny Wiberg | Received |
388-HTA | Outcomes and Costs in Specialized Burn Care: Validation of the Quality Cost Indicator Model for Specialized Burn Care | Raaba Shagari Miriyam Thambithurai | Received |
394-HTA | Exploring PICO Variations in the Context of the European Joint Clinical Assessment | Sakshi Jindal | Received |
403-HTA | Access to Modulating Drugs for Cystic Fibrosis | Sybelle Drumond | Received |
403-EE | The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in Germany | Florian Kron | Received |
404-HTA | Use of Real-World Evidence in HTA Submissions in Emerging Markets | Tanja Babic | Received |
404-EE | Cost-Effectiveness of Rapid Direct Multiplex PCR Test for Diagnosing Meningitis and Encephalitis From the Brazilian Public Perspective | sophie vandepitte | Received |
405-HTA | Taxonomy of the Full Value of mRNA Influenza and COVID-19 Combination Vaccines | Joseph Knee | Received |
410-HTA | Generative AI: A Novel Approach to Data Extraction for NMAS in EU JCA | Cheryl Jones | Received |
414-EE | The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in the Netherlands | Angela Borghouts- de Ruijter | Received |
419-EE | Systematic Literature Review of Cost-Effectiveness Evaluations of Freestyle Libre Continuous Glucose Monitoring Systems | Jack Timmons | Received |
421-EE | A Budget Impact Analysis of Azelastine Hydrochloride/Fluticasone Propionate (AzeFlu) Nasal Spray Suspension for Patients With Allergic Rhinitis (AR) in the Kingdom of Saudi Arabia | Jatin Agarwal | Received |
432-EE | Number Needed to Treat and Associated Costs/Additional Responder of Dupilumab Versus Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | G Kaushik Subramanian | Received |
433-EE | Cost Effectiveness Evidence Overview for Metformin and SGLT2is in Type 2 Diabetes Patients With Cardiorenal Risk: A Targeted Literature Review | Julian Dettenbach | Received |
439-EE | A Multiple Myeloma Case Study for Incorporating Carbon Footprint in Health Technology Assessment | Ruth Chapman | Received |
440-EE | Cost-Effectiveness of Bioabsorbable Nasal Implant (Latera) Versus Conservative Management for the Treatment of Nasal Airway Obstruction (NAO) | Tahlia Seage | Received |
452-EE | Cost Calculator of Immunotherapies in the 1L Endometrial Cancer Treatment From the Brazilian Private Healthcare System Perspective | Abbas Ali | Received |
453-EE | Clinical and Economic Benefits of Adopting Cladribine Tablets for the Treatment of Relapsing: Remitting Multiple Sclerosis in Public Health Service Institutions in Mexico | Margarita Fuentes | Received |
465-EE | The Impact of Time-Dependent Events on Semi-Markov Models With Treatment Sequencing: A Simulation Study | Colleen Dumont | Received |
467-EE | A Cost-Effectiveness Analysis Comparing Two PFO Occluder Devices Using a Markov Model Simulation Over a 5-Year Time Horizon From a Match-Adjusted Indirect Treatment Comparison | Mitesh Nakum | Received |
471-EE | Identifying the Value Drivers in Obesity Treatment: A Targeted Review of Weight Loss Effects on Health Economic Outcomes | Caitlyn Matuska | Received |
479-EE | Real-World Evidence of Healthcare Utilization and Costs for Type 1 Diabetes and Severe Hypoglycemia by Age in Germany | Zara Petzoldt | Received |
484-EE | Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With Relapsed or Refractory High-Grade Glioma in England and Wales | rachid rafia | Received |
485-EE | Exploring the Impact of Changes in Health Valuation Post-COVID-19 Pandemic on an Existing Cost-Effectiveness Analysis | Jasmine Watson | Received |
492-EE | Cost-Effectiveness of CDK4/6 Inhibitors (CDK4/6i) in First- vs Second-Line for Advanced Breast Cancer in the Phase 3 SONIA Trial (BOOG 2017-03) | Seamus Kent | Received |
496-EE | Relugolix/Estradiol/Norethisterone Compared to Tranexamic Acid for Symptomatic Uterine Fibroids in Premenopausal Women (20 to 40 YEAR Old): A Cost-Utility Analysis | Siu Suen Wong | Received |
499-EE | Health Resource Utilization (HRU) and Costs of Patients With Relapsed/Refractory Multiple Myeloma (RRMM) in the United States (US): A Systematic Literature Review | Pardis Lakzadeh | Received |
502-EE | Prevalence, Cost, and Per-Patient Economic Burden of Hospital-Onset Bacteremia and Fungemia | Timothy Kelly | Received |
503-EE | Key Features of Economic Models Used in Submissions to NICE in Dermatology Indications | Caitlyn Matuska | Received |
505-EE | Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Management: A Markov Model for the Canadian Context | Valentyn Litvin | Received |
508-EE | Number Needed to Treat and Cost-per-Event Avoided for Dupilumab Versus Other Asthma Biologics for the Treatment of Moderate-to-Severe Asthma | Kaushik SUBRAMANIAN | Received |
511-EE | Impact of Delayed Treatment Initiation With Resmetirom in Patients With Noncirrhotic Non-Alcoholic Steatohepatitis (NASH) With Moderate to Advanced Fibrosis | Yestle Kim | Received |
517-EE | Cell-Free DNA Epigenomic-Based Test Is Predicted to Be Cost-Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer | Adrian Vilalta | Received |
519-EE | Cost-Effectiveness Analysis of Osteosarcoma Treatment: Insights From a Systemic Literature Review | Aikyadeep Mandal | Received |
528-EE | Cost-Effectiveness Analysis of the TAK-003 Dengue Vaccine Introduction in Argentina | Laura Brion | Received |
532-EE | Budget Impact Analyses of Hemoglobin a1C and Lipid Panel Point-of-Care Testing With Afinion 2 in Italy and Canada | Trisha Whitney | Received |
533-EE | Cost-Effectiveness of Transcatheter Aortic Valve Implantation in Low Surgical Risk Symptomatic Severe Aortic Stenosis Patients in Brazil | Archita Sarmah | Received |
536-EE | The Benefit of Introducing Remimazolam for General Anesthesia in Belgian Clinical Practice | Attila Mihalik | Received |
540-EE | Cost-Effectiveness of Next Generation Sequencing to Select Microsatellite Stable/Mismatch Repair Proficient Metastatic Colorectal Cancer Patients for Immune Checkpoint Inhibitor Therapy | Benjamin Peter Geisler | Received |
542-EE | Long-Term Extrapolation of Overall Survival (OS) and Progression-Free Survival (PFS) for the Lunar Trial in Metastatic Non-Small Cell Lung Cancer (NSCLC) Following Progression on Platinum-Based Therapy | Fernando Nino de Rivera | Received |
543-EE | Hospital Healthcare Resource Utilization in People With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor in Portugal: A Non-Interventional, Retrospective Study | Shivali Arora | Received |
562-EE | Public Health Impact and Cost-Effectiveness of Replacing PCV13 With PCV15 in the National Immunization Program in Saudi Arabia | Ghadah Albassam | Received |
566-EE | Real-World Evidence of Multi-Gene Panel Sequencing Effectiveness and Cost-Effectiveness for Advanced Cancers: A Tumor-Agnostic Target Trial Emulation | Emanuel Krebs | Received |
580-EE | Cost-Utility of Acromegaly Second Line Pharmacological Treatments in Adult Patients in France | Haifa BEN ROMDHANE | Received |
601-EE | Using Dupilumab in Line With the England NICE Recommendation (TA534): Impact on the Healthcare Resource Utilization and Non-Medicine Cost | G Kaushik Subramanian | Received |
602-EE | Cost-Effectiveness of Universal Screening for Hypothyroidism in Pregnant Women in Indonesia and Mexico | Julian Dettenbach | Received |
616-EE | Cost of Illness Study of Inherited Retinal Diseases in the Netherlands in 2023 | Loek Lennaerts | Received |
631-EE | Cost-Effectiveness of Difelikefalin Compared to Best Supportive Care for Treatment of Chronic Kidney Disease-Associated Pruritus in Australia | Scott Brydon | Received |
638-EE | Long COVID: A Costly Condition Imposing Substantial Burden on Society | Naomi Stapleton | Received |
643-EE | Assessing Healthcare Payer Perspective on Health Economic Model Transparency and Applicability to Own Setting | Oleksandr Topachevskyi | Received |
648-EE | Micro-Costing Study of Comprehensive Genomic Profiling for Implementation of Precision Cancer Medicine in Public Healthcare Systems: The Norwegian Infrastructure for Precision Diagnostics and Impress-Norway Trial | Pia Sofie Henkel | Received |
651-EE | Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With Low-Grade Glioma Requiring Systemic Treatment in England and Wales | Rachid Rafia | Received |
668-EE | Assessing the Impact of a Virtual Maternity Care Program on Total Cost of Care in a US Medicaid-Insured Population | Sara Crow | Received |
669-EE | Analysis of the Costs and Carbon Footprint Associated With Reusable Flexible Cystoscopes: Implications for the Utilization of Single-Use Digital Flexible Cystoscopes | Timothy Kelly | Received |
670-EE | Impact of Different Mapping Algorithms From Disease-Specific Measures to EQ-5D on Cost-Effectiveness Analysis in Atopic Dermatitis | Tomohiro Kondo | Received |
676-EE | Economic Burden and Unmet Needs of Retinitis Pigmentosa: Expert Perspective in Brazil and Mexico | Yann Boixel | Received |
685-EE | What Is the Real Price of Switching Medical Technologies? Evaluation of Financial and Value-Based Aspects: The Case for Dialysis | Sophie Boeger | Received |
690-EE | The Impact of Caring for an Infant With Respiratory Syncytial Virus on Work-Related Outcomes: Insights From Caregivers Recruited From Canada, Germany, Italy, and Netherlands | Nemin Chen | Received |
699-EE | The Benefit of Introducing Remimazolam for Procedural Sedation in Belgian Clinical Practice | Attila Mihalik | Received |
708-EE | Assessment of Direct Costs of Human Papillomavirus Related Diseases in Saudi Arabia | Carole Mamane | Received |
714-EE | Identifying Patients With High Economic Burden Using Real-World Data: The Case of Myasthenia Gravis (MG) | Ingrid Schager | Received |
717-EE | Influence on Antibiotic Prescribing and Cost Effects Through Standardized Implementation of PoC Testing in Adults With Sore Throats in Standard SHI Care | Jana Schlosser | Received |
725-EE | Cost-Effectiveness of Linzagolix for Uterine Fibroids in Australia: A Healthcare Payer and Societal Perspective | Tahlia Seage | Received |
727-EE | Determining Survival Impact and Cost-Effectiveness of Multi-Gene Panel Sequencing in Metastatic Colorectal Cancer With Super Learning Approaches | Emanuel Krebs | Received |
730-EE | Health Care Resource Utilization (HCRU) in Chronic Obstructive Pulmonary Disease (COPD), and Asthma Patients With Moderate-to-Severe Disease | Ali Siddiqui | Received |
738-EE | Economic Value of Dupilumab and Advanced Therapeutics in Patients With Type 2 Inflammatory Diseases in Italy: An Estimation of Healthcare Resource Utilization Cost Offsets | Ali Siddiqui | Received |
740-EE | Cost-Effectiveness of Glycopyrronium Bromide Oral Solution for the Management of Severe Sialorrhea in Children With Cerebral Palsy in Poland | Grzegorz Binowski | Received |
741-EE | Budget Impact Analysis of Risdiplam in the Treatment of Newborn Spinal Muscular Atrophy Patients in Poland | Grzegorz Binowski | Received |
749-EE | Socioeconomic Disparities in Hypertension Medication Adherence in Quezon City: A Cross-Sectional Study | Ina Mulingbayan | Received |
759-EE | Cost-Effectiveness of Tezepelumab in Taiwan for Severe Asthma | Nora Lin | Received |
774-EE | Growth and Economic Trends of European CROs: Insights From the EUCROF Benchmarking Project | Hedda Magnusson | Received |
790-EE | Cost-Effectiveness and Cost Utility Analysis of an eHealth Peer-Led Wheelchair Training Program Compared to the Existing Wheelchair Training Practice in Canadian Rehabilitation Centers: Economic Evaluation of a RCT | Maude Laberge | Received |
791-EE | Cost-Effectiveness Analysis of 1.5 Ruxolitinib Cream for the Treatment of Patients With Atopic Dermatitis in Canada | Mehdi Larbi | Received |
794-EE | Assessing the Impact of Introducing Mavacamten for the Treatment of Obstructive HCM on the Modelled System and Societal Level Burden in China | JIA YU | Received |
803-EE | Systematic Review of Healthcare Costs and Resource Utilization in Fibromyalgia in European Countries and the US | Nidhun Praveen | Received |
814-EE | Potential return on subscription to smart phone based digital health risk assessment | Laura Wilson | Received |
824-EE | Are Standard Economic Evaluations Suitable for Evaluating Life-Extending Innovations in Kidney Care? | Sophie Boeger | Received |
829-EE | Quantifying Disease-Specific Indirect Economic Burden Using Survey Research Methods as a Component of Estimating the Total Economic Burden of a Disease | Jasmine Watson | Received |
832-EE | The Lifetime Return on Investment of Measles, Mumps, and Rubella Vaccination in Belgium and Poland | Ugne Sabale | Received |
835-EE | Improper Age-Adjustment of Health State Utilities in Cost-Effectiveness Models: Assessing the Impact and Key Drivers | Walter Morris | Received |
17-20 November Barcelona
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|